Stock Research for GHDX


Featured Broker: Ally Invest

Get the due diligence for another stock.


GHDX Stock Chart & Research Data

The GHDX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GHDX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GHDX Due diligence Resources & Stock Charts

The GHDX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GHDX Detailed Price Forecast - CNN Money CNN View GHDX Detailed Summary - Google Finance
Yahoo View GHDX Detailed Summary - Yahoo! Finance Zacks View GHDX Stock Research & Analysis -

Stock Analysis

TradeIdeas View GHDX Trends & Analysis - Trade-Ideas Barrons View GHDX Major Holders - Barrons
NASDAQ View GHDX Call Transcripts - NASDAQ Seeking View GHDX Breaking News & Analysis - Seeking Alpha
Spotlight View GHDX Annual Report - OTC Report View GHDX OTC Short Report -
TradeKing View GHDX Fundamentals - TradeKing Charts View GHDX SEC Filings - Bar Chart
WSJ View Historical Prices for GHDX - The WSJ Morningstar View Performance/Total Return for GHDX - Morningstar
MarketWatch View the Analyst Estimates for GHDX - MarketWatch CNBC View the Earnings History for GHDX - CNBC
StockMarketWatch View the GHDX Earnings - StockMarketWatch MacroAxis View GHDX Buy or Sell Recommendations - MacroAxis
Bullish View the GHDX Bullish Patterns - American Bulls Short Pains View GHDX Short Pain Metrics -

Social Media Mentions

StockTwits View GHDX Stock Mentions - StockTwits PennyStocks View GHDX Stock Mentions - PennyStockTweets
Twitter View GHDX Stock Mentions - Twitter Invest Hub View GHDX Investment Forum News - Investor Hub
Yahoo View GHDX Stock Mentions - Yahoo! Message Board Seeking Alpha View GHDX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GHDX - Insider Cow View Insider Transactions for GHDX - Insider Cow
CNBC View GHDX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GHDX - OTC Markets
Yahoo View Insider Transactions for GHDX - Yahoo! Finance NASDAQ View Institutional Holdings for GHDX - NASDAQ

Stock Charts

FinViz View GHDX Stock Insight & Charts - StockCharts View GHDX Investment Charts -
BarChart View GHDX Stock Overview & Charts - BarChart Trading View View GHDX User Generated Charts - Trading View

Latest Financial News for GHDX

Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?
Posted on Wednesday September 12, 2018

Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.

Epic Sciences Announces Completion of $52 Million Series E Financing
Posted on Wednesday September 12, 2018

SAN DIEGO, Sept. 12, 2018 /PRNewswire/ -- Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (VAR). Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing. "We are extremely pleased to have such a strong and diverse syndicate with leaders from the private payer industry, diagnostic strategics, innovators from the technology space, and best-in-class healthcare crossover investors," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences.

[$$] Epic Sciences Gets $52 Million for Cancer Blood Tests
Posted on Wednesday September 12, 2018

Epic Sciences Inc. has gathered $52 million to pursue of goal of arming physicians with better information for treating cancer patients.

German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Posted on Friday September 07, 2018

Updated Assessment of Breast Cancer Gene Expression Profiling Tests for Clinical Use in Germany Final German Federal Joint Committee (G-BA) Reimbursement Decision Expected by End of 2018 REDWOOD CITY, ...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.